Prostate cancer (PCa) is a prevalent malignancy that occurs primarily in old males. Prostate
tumors in different patients manifest significant inter-patient heterogeneity with respect to …

Prostate cancer is the second most common malignancy in men worldwide. Prostate cancer
can be treated by surgery, radiotherapy and hormone therapy. The latter, in the form of …

Drug resistance is the main obstacle to achieving a cure in many cancer patients. Reactive
oxygen species (ROS) are master regulators of cancer development that act through …

The dynamic regulation of chromatin accessibility is one of the prominent characteristics of
eukaryotic genome. The inaccessible regions are mainly located in heterochromatin, which …

Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited treatment
options. TNBC progression is associated with expansion of cancer stem cells (CSCs). Few …

Bladder cancer is a malignant tumor of the urinary system and is one of the most common
cancers worldwide. Lipoxygenases are closely related to the development of various …

Prostate cancer (PCa) is a malignant disorder of prostate gland being asymptomatic in early
stages and high metastatic potential in advanced stages. The chemotherapy and surgical …

Abstract The polybromo-1 (PBRM1) chromatin-targeting subunit of the SWI/SNF PBAF
chromatin remodeling complex drives DNA damage resistance and immune evasion in …

Epidermal growth factor receptor variant III (EGFRvIII) is a mutant isoform of EGFR with a
deletion of exons 2–7 making it insensitive to EGF stimulation and downstream signal …

Chronic inflammation promotes epigenetic reprogramming in cancer progression by
pathways that remain unclear. The oncogenic MUC1-C protein is activated by the …